RxPros Review
Best for: price-sensitive patients comfortable with annual prepayment to lock in the lowest compounded GLP-1 monthly rate in the market
RxPros (rxpros.com) is a Wyoming-incorporated compounded GLP-1 telehealth platform (RxPros LLC, 1309 Coffeen Ave Ste 15880, Sheridan, WY 82801). LegitScript Certified. Compounded semaglutide $99.99/month and compounded tirzepatide $144.97/month at the introductory + paid-annually tier. Includes the doctor visit, medication, and overnight cold shipping. Add-on options for Zofran (anti-nausea) and B12.
Medium confidence · Last verified 2026-05-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
RxPros is one of the most affordable GLP-1 options on the market.
Score Breakdown
Drugs Offered
RxPros prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (intro / paid annually) | compounded | $99.99 |
| Compounded tirzepatide (intro / paid annually) | compounded | $144.97 |
✓ Pros
- •$99.99/month compounded semaglutide is in the cheapest decile of the US compounded telehealth market — competitive with the lowest-priced peer platforms
- •$144.97/month compounded tirzepatide is at the lower end of the tirzepatide compounded range
- •LegitScript Certified seal displayed
- •Named legal entity (RxPros LLC) with physical Wyoming address — better entity transparency than peer platforms that show only a brand name
- •Overnight cold-packed shipping disclosed (important for GLP-1 cold-chain integrity)
- •FDA-regulated 503A pharmacies referenced
- •Add-on Zofran (anti-nausea) and B12 available — useful for patients managing GI side effects during titration
✗ Cons
- •Headline pricing requires annual prepayment OR is presented as 'introductory' — month-to-month and quarterly pricing tiers not clearly disclosed on the home page
- •Per-state availability NOT enumerated publicly — verify your state ships before committing
- •Specific 503A pharmacy partner names NOT publicly disclosed — material YMYL transparency gap
- •State of incorporation NOT explicitly stated (Wyoming address suggests WY incorporation but not confirmed)
- •Lab work NOT included as standard
- •LegitScript certification number NOT publicly displayed (seal-only)
Ready to start with RxPros?
Starting at $99.99/month. See current pricing and start your free consultation.
Sources & methodology
Our RxPros review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to RxPros
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with RxPros?
Starting at $99.99/month. See current pricing and start your free consultation.